Insulet (PODD) EBT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.49% |
| Dec 31, 2025 | 57.13% |
| Sep 30, 2025 | 55.75% |
| Jun 30, 2025 | 10.29% |
| Mar 31, 2025 | 83.03% |
| Dec 31, 2024 | 74.93% |
| Sep 30, 2024 | 137.37% |
| Jun 30, 2024 | 93.17% |
| Mar 31, 2024 | 63.49% |
| Dec 31, 2023 | 58.28% |
| Sep 30, 2023 | 96.07% |
| Jun 30, 2023 | 89.26% |
| Mar 31, 2023 | 42.83% |
| Dec 31, 2022 | 39.11% |
| Sep 30, 2022 | -22.03% |
| Jun 30, 2022 | -36.33% |
| Mar 31, 2022 | 37.78% |
| Dec 31, 2021 | 41.78% |
| Sep 30, 2021 | 48.21% |
| Jun 30, 2021 | -45.97% |
| Mar 31, 2021 | 15.19% |
| Dec 31, 2020 | -3.23% |
| Sep 30, 2020 | 22.40% |
| Jun 30, 2020 | 24.64% |
| Mar 31, 2020 | 24.24% |
| Dec 31, 2019 | 40.86% |
| Sep 30, 2019 | 16.01% |
| Jun 30, 2019 | 15.61% |
| Mar 31, 2019 | 22.63% |
| Dec 31, 2018 | 43.54% |
| Sep 30, 2018 | 15.85% |
| Jun 30, 2018 | 34.24% |
| Mar 31, 2018 | 9.95% |
| Dec 31, 2017 | 7.26% |
| Sep 30, 2017 | 29.84% |
| Jun 30, 2017 | 11.85% |
| Mar 31, 2017 | 7.68% |
| Dec 31, 2016 | 8.82% |
| Sep 30, 2016 | 26.29% |
| Jun 30, 2016 | 26.08% |
| Mar 31, 2016 | -1.53% |
| Dec 31, 2015 | 5.43% |
| Sep 30, 2015 | -8.20% |
| Jun 30, 2015 | -4.70% |